Pebblebrook Hotel (PEB) Stock “Buy” Rating Maintained at RBC Capital; The Price Target Given is $35.0000; Novabay Pharmaceuticals (NYSEMKT:NBY) Sellers Decreased By 8.95% Their Shorts

July 17, 2017 - By Hazel Jackson

Among 12 analysts covering Pebblebrook Hotel Trust (NYSE:PEB), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Pebblebrook Hotel Trust has $52 highest and $27.0 lowest target. $34.06’s average target is 2.68% above currents $33.17 stock price. Pebblebrook Hotel Trust had 37 analyst reports since July 21, 2015 according to SRatingsIntel. Barclays Capital initiated the stock with “Overweight” rating in Tuesday, July 21 report. The stock of Pebblebrook Hotel Trust (NYSE:PEB) earned “Outperform” rating by Credit Suisse on Friday, December 11. Boenning & Scattergood maintained the shares of PEB in report on Wednesday, April 19 with “Neutral” rating. The firm has “Overweight” rating given on Saturday, August 15 by Barclays Capital. The stock has “Outperform” rating by Credit Suisse on Wednesday, March 23. The stock of Pebblebrook Hotel Trust (NYSE:PEB) earned “Overweight” rating by Barclays Capital on Wednesday, November 23. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, March 29. Evercore maintained the shares of PEB in report on Monday, September 7 with “Hold” rating. The firm has “Outperform” rating by RBC Capital Markets given on Monday, May 2. Zacks downgraded the shares of PEB in report on Wednesday, August 12 to “Buy” rating.

Novabay Pharmaceuticals Incorporated (NYSEMKT:NBY) had a decrease of 8.95% in short interest. NBY’s SI was 93,600 shares in July as released by FINRA. Its down 8.95% from 102,800 shares previously. With 17,000 avg volume, 6 days are for Novabay Pharmaceuticals Incorporated (NYSEMKT:NBY)’s short sellers to cover NBY’s short positions. The SI to Novabay Pharmaceuticals Incorporated’s float is 1.86%. The stock decreased 4.82% or $0.2 on July 14, reaching $3.95. About shares traded. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has risen 7.90% since July 17, 2016 and is uptrending. It has underperformed by 8.80% the S&P500.

Pebblebrook Hotel Trust is an internally managed hotel investment company. The company has market cap of $2.31 billion. The Firm is a real estate investment trust that acquires and invests in hotel properties located primarily in cities of the United States. It has a 48.07 P/E ratio. As of December 31, 2016, the Company owned 29 hotels with a total of 7,219 guest rooms.

Investors sentiment increased to 1.07 in Q4 2016. Its up 0.20, from 0.87 in 2016Q3. It improved, as 24 investors sold Pebblebrook Hotel Trust shares while 64 reduced holdings. 31 funds opened positions while 63 raised stakes. 81.93 million shares or 5.75% less from 86.94 million shares in 2016Q3 were reported. Edge Asset Mgmt Incorporated accumulated 1.64M shares. Security & Management reported 636,695 shares. American Gp Inc accumulated 41,138 shares. Stifel reported 165,770 shares. Westpac Corp stated it has 178,144 shares. Kbc Gp Inc Nv holds 0.02% or 53,081 shares in its portfolio. First Tru Advsr Lp holds 0.01% or 104,698 shares in its portfolio. Panagora Asset Mgmt holds 0% in Pebblebrook Hotel Trust (NYSE:PEB) or 1,710 shares. Federated Investors Inc Pa reported 10,172 shares stake. Quantbot Tech Ltd Partnership holds 0.05% in Pebblebrook Hotel Trust (NYSE:PEB) or 14,785 shares. Alliancebernstein Limited Partnership owns 155,590 shares. Silvercrest Asset Group Lc reported 4.66M shares or 1.55% of all its holdings. Gsa Cap Prtnrs Llp accumulated 7,200 shares. Great West Life Assurance Can holds 0% of its portfolio in Pebblebrook Hotel Trust (NYSE:PEB) for 52,656 shares. Victory Capital Mgmt reported 2,925 shares stake.

The stock increased 0.15% or $0.05 on July 14, reaching $33.17. About shares traded. Pebblebrook Hotel Trust (NYSE:PEB) has risen 32.44% since July 17, 2016 and is uptrending. It has outperformed by 15.74% the S&P500.

Since March 21, 2017, it had 0 insider purchases, and 3 insider sales for $1.58 million activity. The insider Fisher Thomas Charles sold $357,406. $864,742 worth of Pebblebrook Hotel Trust (NYSE:PEB) was sold by BORTZ JON E. Martz Raymond D sold $358,158 worth of stock or 12,828 shares.

Analysts await Pebblebrook Hotel Trust (NYSE:PEB) to report earnings on July, 27 after the close. They expect $0.68 earnings per share, down 16.05% or $0.13 from last year’s $0.81 per share. PEB’s profit will be $47.36M for 12.19 P/E if the $0.68 EPS becomes a reality. After $0.54 actual earnings per share reported by Pebblebrook Hotel Trust for the previous quarter, Wall Street now forecasts 25.93% EPS growth.

Among 4 analysts covering Novabay Pharmaceuticals Inc (NYSEMKT:NBY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Novabay Pharmaceuticals Inc had 5 analyst reports since November 20, 2015 according to SRatingsIntel. Rodman & Renshaw initiated the stock with “Buy” rating in Monday, February 6 report. The firm earned “Buy” rating on Monday, December 14 by Maxim Group. The stock of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has “Buy” rating given on Monday, March 27 by Laidlaw. Roth Capital initiated it with “Buy” rating and $5.50 target in Monday, June 5 report.

NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The company has market cap of $56.10 million. The Firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. It currently has negative earnings. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: